Ardelyx (ARDX) earnings

ARDELYX, INC.

Results to: Jun 2026
Latest analysed call: Jun 2026 (Q2 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Ardelyx earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	121 $ million	+23.8% YoY	Quarterly, as filed	Quarter to Jun 2026	Revenue from operations as filed.
Operating margin	-10.3 %	+4.5 pts YoY	Operating profit / revenue	Quarter to Jun 2026	For the quarter; a change is in percentage points.
Net profit	-16.7 $ million	—	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Price

$3.27 +2.51% · +$0.08

Last close Oct 15, 2026 · US · USD

Performance −34.7% 1Y

1Y: $5.01 on 14 Oct 2025 → $3.27. High $7.99 (21 Jan 2026), low $3.12 (13 Oct 2026).

Previous close: $3.19
52-week range: $3.12 – $7.99
One year: −36.26%

Overview

Symbol: ARDX
Exchange: US
Currency: USD

Financials

What the filings say

Net profit, year on year: +12% (quarter to jun 2026 against jun 2025).

In $ million. Oldest period first.

Line item	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	98	116	74	98	110	125	94	121
Expenses	80	90	110	112	102	149	127	133
Operating profit	2	8	-36	-14	5	5	-33	-12
Operating margin	2.3%	7.0%	−49.0%	−14.7%	4.2%	4.1%	−34.7%	−10.3%
Other income	2	2	2	2	2	2	2	2
Interest	3	4	4	4	6	6	6	5
Profit before tax	-1	5	-40	-19	-1	-0	-38	-17
Tax rate	−5.6%	0.8%	−2.1%	−0.0%	−11.8%	−1.8%	−0.0%	−0.7%
Net profit	-1	5	-41	-19	-1	-0	-38	-17
EPS ($ per share)	0	—	-0.17	-0.08	0	—	-0.15	-0.07

Source: Inve data · income statement, quarterly · to Jun 2026

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity capital	0	0	0	0	0	0	0	0
Reserves	-366	-460	-555	-713	-780	-846	-885	-947
Total liabilities	68	73	75	67	92	131	262	335
Fixed assets	6	3	2	2	1	1	1	2
Total assets	183	260	202	150	190	298	436	502

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	-70	-76	-81	-153	-70	-90	-45	-42
Cash from investing	-30	23	-31	51	18	-131	-18	-9
Cash from financing	104	155	23	83	75	146	107	55
Net cash flow	—	102	-90	-19	24	-75	43	3
Capital expenditure	-0	-0	-0	-2	-0	-0	-1	-1
Free cash flow	-71	-77	-82	-154	-70	-90	-46	-44

Source: Inve data · cash flow · to Dec 2025

Insider filings

104 filings between Nov 21, 2025 and Aug 21, 2026.

Open market

decisions to buy or sell

Purchases

$1.95M

1 purchase by 1 insider

Sales

$4.30M

78 sales by 9 insiders

10% filed under a 10b5-1 plan — scheduled in advance, not decided on the day

Compensation

not trading decisions

17: Award — granted as compensation
8: Option exercise — converted options into shares

Who traded

open market only

Insider	Bought	Sold	Last filing
RAAB MICHAEL	—	$2.57M	Aug 21, 2026
MOTT DAVID M	$1.95M	—	Feb 20, 2026
Williams Laura A	—	$1.01M	Aug 21, 2026
Foster Eric Duane	—	$176.4K	Aug 21, 2026
Kelliher Mike	—	$162.2K	Aug 21, 2026
Reilly Joseph James	—	$129.2K	Aug 21, 2026
Bishop John E	—	$109.2K	Aug 21, 2026
Brady James Parker	—	$84.8K	Aug 21, 2026

Latest filings (50)

Date	Insider	What	Shares	Value
Aug 21, 2026	RAAB MICHAEL President & CEO	Sale	19,178	$74.0K
Aug 21, 2026	Kelliher Mike Chief Business Officer	Sale	3,104	$12.0K
Aug 21, 2026	Foster Eric Duane Chief Commercial Officer	Sale	2,575	$9.9K
Aug 21, 2026	Hohenleitner Susan Chief Financial Officer	Sale	1,558	$6.0K
Aug 21, 2026	Brady James Parker Chief Human Resources Officer	Sale	13,160	$50.8K
Aug 21, 2026	Foster Eric Duane Chief Commercial Officer	Sale	2,598	$10.0K
Aug 21, 2026	Williams Laura A Chief Patient Officer	Sale	3,089	$11.9K
Aug 21, 2026	Reilly Joseph James See Remarks	Sale	2,872	$11.1K
Aug 21, 2026	RAAB MICHAEL President & CEO	Sale	8,411	$32.4K
Aug 21, 2026	RAAB MICHAEL President & CEO	Sale	15,009	$57.9K
Aug 21, 2026	Brady James Parker Chief Human Resources Officer	Sale	1,976	$7.6K
Aug 21, 2026	Kelliher Mike Chief Business Officer	Sale	2,002	$7.7K
Aug 21, 2026	Foster Eric Duane Chief Commercial Officer	Sale	3,389	$13.1K
Aug 21, 2026	Williams Laura A Chief Patient Officer	Sale	3,486	$13.4K
Aug 21, 2026	RAAB MICHAEL President & CEO	Sale	15,976	$61.6K
Aug 21, 2026	Reilly Joseph James See Remarks	Sale	1,110	$4.3K
Aug 21, 2026	Williams Laura A Chief Patient Officer	Sale	1,734	$6.7K
Aug 21, 2026	Williams Laura A Chief Patient Officer	Sale	2,430	$9.4K
Aug 21, 2026	Bishop John E See Remarks	Sale	17,281	$66.7K
Aug 21, 2026	Kelliher Mike Chief Business Officer	Sale	2,652	$10.2K
Aug 21, 2026	Bishop John E See Remarks	Sale	2,469	$9.5K
Jul 15, 2026	RAAB MICHAEL President & CEO	Option exercise 10b5-1 plan	20,834	$20.6K
Jul 15, 2026	RAAB MICHAEL President & CEO	Sale 10b5-1 plan	41,668	$210.9K
Jun 18, 2026	Williams Laura A Chief Patient Officer	Sale 10b5-1 plan	81,898	$490.5K
Jun 18, 2026	Williams Laura A Chief Patient Officer	Option exercise 10b5-1 plan	31,000	$30.7K
Jun 16, 2026	Rodgers Richard J Director	Award	26,455	$0
Jun 16, 2026	Bertrand William C JR Director	Award	26,455	$0
Jun 16, 2026	Bertrand William C JR Director	Award	12,345	$0
Jun 16, 2026	MOTT DAVID M Director	Award	26,455	$0
Jun 16, 2026	Bazemore Robert B Director	Award	26,455	$0
Jun 16, 2026	MOTT DAVID M Director	Award	20,282	$0
Jun 16, 2026	Parsey Merdad Director	Award	26,455	$0
Jun 16, 2026	Bhanji Muna Director	Award	26,455	$0
Jun 16, 2026	Cadoret-Manier Onaiza Director	Award	26,455	$0
Jun 15, 2026	RAAB MICHAEL President & CEO	Sale 10b5-1 plan	41,666	$236.3K
Jun 15, 2026	RAAB MICHAEL President & CEO	Option exercise 10b5-1 plan	20,833	$20.6K
May 21, 2026	Foster Eric Duane Chief Commercial Officer	Sale	2,427	$15.2K
May 21, 2026	Foster Eric Duane Chief Commercial Officer	Sale	3,166	$19.8K
May 21, 2026	Kelliher Mike Chief Business Officer	Sale	2,478	$15.5K
May 21, 2026	Kelliher Mike Chief Business Officer	Sale	2,900	$18.2K
May 21, 2026	Williams Laura A Chief Patient Officer	Sale	2,157	$13.5K
May 21, 2026	Williams Laura A Chief Patient Officer	Sale	1,503	$9.4K
May 21, 2026	RAAB MICHAEL President & CEO	Sale	14,028	$87.9K
May 21, 2026	RAAB MICHAEL President & CEO	Sale	17,926	$112.4K
May 21, 2026	RAAB MICHAEL President & CEO	Sale	7,861	$49.3K
May 21, 2026	Kelliher Mike Chief Business Officer	Sale	1,870	$11.7K
May 21, 2026	RAAB MICHAEL President & CEO	Sale	14,933	$93.6K
May 21, 2026	Bishop John E See Remarks	Sale	2,306	$14.5K
May 21, 2026	Williams Laura A Chief Patient Officer	Sale	1,418	$8.9K
May 21, 2026	Williams Laura A Chief Patient Officer	Sale	1,911	$12.0K

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for ARDELYX, INC.

Free account. Everything above stays public.

Write why you follow ARDELYX, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

Create your Inve Case What an account adds

Keep reading

Other US companies filed under A

All 347 companies under A

US companies A–Z · Earnings calls · US earnings-call directory · US sector analysis · What management promised, and delivered

Ardelyx (ARDX) earnings

The figures, each with its period

Performance −34.7% 1Y

Jun 2026 (Q2 FY26) — Aug 6, 2026

Ardelyx earnings calls (ARDX)

What the filings say

Insider filings

Open market

Compensation

Who traded

Start an Inve Case for ARDELYX, INC.

Other US companies filed under A